Physician
Agape Pain Management and Anesthesia, LLC
Agape Pain Management and Anesthesia, LLC was paid $2.49M by Medicaid between Jan 2018 and Dec 2024, across 42 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 42% of everything it billed.
33Billing provider infoAGAPE PAIN MANAGEMENT AND ANESTHESIA, LLC
LAS CRUCES, NM 88001
LAS CRUCES, NM 88001
33aNPI1891076519assigned 09/08/2011
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$2.49M
24GClaims56,728
24DCodes billed42
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in New Mexico
Rank by total paid#1 of 11
Median peer was paid$160K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,445 | $130K | |
| 2019 | 3,108 | $162K | |
| 2020 | 7,720 | $369K | |
| 2021 | 12,758 | $443K | |
| 2022 | 12,575 | $464K | |
| 2023 | 12,577 | $555K | |
| 2024incomplete | 5,545 | $364K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 42% | 16,774 | 15,468 | $1.04M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 13% | 7,037 | 6,646 | $314K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 8.1% | 6,799 | 1,981 | $203K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 3,691 | 3,419 | $184K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.2% | 5,929 | 1,786 | $180K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.1% | 700 | 668 | $78K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.2% | 1,098 | 1,073 | $54K |
| 97032 | 1.9% | 4,238 | 1,506 | $48K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 453 | 443 | $48K |
| 64635 | 1.9% | 211 | 167 | $48K | |
| 64493 | 1.4% | 252 | 237 | $35K | |
| 97163 | 1.4% | 608 | 585 | $34K |
30 more codes
| 64636 | 1.4% | 246 | $34K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 1.1% | 3,889 | $26K |
| 99205 | Prolong outpt/office vis | <1% | 171 | $23K |
| 64494 | <1% | 253 | $20K | |
| 97035 | <1% | 1,998 | $17K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 319 | $17K |
| 64495 | <1% | 131 | $11K | |
| 27096 | <1% | 88 | $10K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 128 | $10K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 102 | $10K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 263 | $7K |
| 99423 | <1% | 80 | $6K | |
| 64625 | <1% | 32 | $6K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 19 | $4K |
| 99201 | <1% | 61 | $3K | |
| 97162 | <1% | 59 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 100 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 27 | $2K |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 196 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 58 | $1K |
| 99490 | Ccm add 20min | <1% | 125 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 26 | $979.48 |
| 99422 | <1% | 21 | $836.45 | |
| 99421 | <1% | 18 | $586.34 | |
| 86328 | <1% | 13 | $399.79 | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 18 | $386.10 |
| 99406 | <1% | 28 | $294.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 312 | $269.45 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 41 | $11.86 |
| 99072 | 0% | 116 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, LLEWELYN (MD/OWNER)
| Provider | Location | Paid |
|---|---|---|
| Agape Physical Therapy & Wellness Center LLC | Las Cruces, NM | $232K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.